肝细胞癌分子靶向治疗现况与展望

Current status and prospects of the molecular targeted therapy on hepatocellular carcinoma

肝细胞癌是常见的恶性程度较高的肿瘤之一,自然生存时间短,手术切除率低,且易转移复发,临床急需新的治疗方法。近年来,以索拉非尼为代表的靶向治疗给中晚期肝癌患者带来了新希望。本文从靶向治疗的机制、靶向药物治疗研究、靶向治疗与常规治疗手段的综合、靶向治疗的疗效评价存在问题及建议等方面进行综述,并对其前景进行展望。

Hepatocellular carcinoma is a common malignant tumors, the natural survival time is short, surgical re- section rate is low, and easy to develop metastasis and recurrence, new treatments are urgent needed. In recent years, as the representative of sorafenib, targeted therapy brings new hope to the HCC patients. In this paper, the mechanism of targeted therapy, the targeted drugs applying in clinic, targeted therapy eonbined with conventional treatments are reviewed, problems and suggestions in the evaluation of the targeted therapy are also mentioned, and its prospects is analyzed additionally.